Colgate New Product Pipeline Gains Wall Street Favor; Stock Rises 8% In Q3
This article was originally published in The Tan Sheet
Colgate-Palmolive's healthy second quarter financials, coupled with an emphasis on new products launching by year end and a significant accompanying advertising spend, have earned Wall Street's approval despite current economic uncertainties in the market
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC